Synvisc‑One 6 ml

Synvisc

Prescription injectable medicine

Viscosupplement / hyaluronic acid joint injection

Sterile, non‑pyrogenic pre Filled syringe – manufactured and distributed under regulatory approvals (e.g. by Sanofi/Genzyme). :contentReference[oaicite:21]{index=21}

Sterile, non‑pyrogenic pre Filled syringe – manufactured and distributed under regulatory approvals (e.g. by Sanofi/Genzyme). :contentReference[oaicite:21]{index=21}

Viscosupplement / hyaluronic acid joint injection

Description

Synvisc‑One is a sterile, pre‑filled 6 ml syringe containing hylan G‑F 20 (cross‑linked hyaluronic acid) intended for intra‑articular injection into the knee joint. It supplements the joint’s synovial fluid to provide lubrication and shock absorption, aiming to relieve pain and improve mobility in patients with osteoarthritis of the knee. :contentReference[oaicite:0]{index=0}

Bnefits

Acts as a lubricant and cushion in the knee joint, helping to reduce pain and improve joint function in osteoarthritis. :contentReference[oaicite:1]{index=1}
Single‑injection treatment — only one injection required instead of multiple doses. :contentReference[oaicite:2]{index=2}
May provide up to six months of symptomatic relief. :contentReference[oaicite:3]{index=3}
Sterile and non‑pyrogenic formulation, designed for intra‑articular use under medical supervision. :contentReference[oaicite:4]{index=4}

Indications

Pain associated with osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. :contentReference[oaicite:5]{index=5}

Composition

Hylan G-F 20 (cross‑linked hyaluronic acid) 8.0 mg per ml, plus excipients: sodium chloride 8.5 mg/ml, disodium hydrogen phosphate 0.16 mg/ml, sodium dihydrogen phosphate hydrate 0.04 mg/ml, water for injection q.s. to 1 ml. :contentReference[oaicite:6]{index=6}

Formulation

Sterile, non‑pyrogenic, pre-filled 6 ml glass syringe containing viscous hyaluronan solution (gel‑like) for intra‑articular injection. :contentReference[oaicite:7]{index=7}

Packaging

1 × 6 ml pre-filled glass syringe (single-dose) per pack. :contentReference[oaicite:8]{index=8}

Usage

To be administered by a qualified physician or properly licensed practitioner via intra‑articular injection into the knee joint. Usage requires aseptic technique. :contentReference[oaicite:9]{index=9}
If synovial fluid or effusion is present, it should be removed before injection. Do not use the same syringe for fluid removal and injection. Use an 18–20 gauge needle. Inject the full 6 ml in one knee only. :contentReference[oaicite:10]{index=10}
After injection, patients should avoid strenuous activity, high-impact sports or prolonged standing for at least 48 hours. :contentReference[oaicite:11]{index=11}

Contraindications

Known hypersensitivity to hyaluronan products or any component of the formulation (e.g. hylan G-F 20). :contentReference[oaicite:14]{index=14}
Infection in or around the target knee joint, or skin disease at the injection site. :contentReference[oaicite:15]{index=15}
Venous or lymphatic stasis in the leg to be injected. :contentReference[oaicite:16]{index=16}

Adverse Effects

Injection‑site reactions including pain, swelling, warmth, joint effusion. :contentReference[oaicite:17]{index=17}
Joint stiffness, arthralgia, arthropathy, gait disturbance in some cases. :contentReference[oaicite:18]{index=18}
Rare hypersensitivity reactions, potentially including allergic reactions in individuals sensitive to avian‑derived hyaluronan (e.g. allergy to birds, feathers, or egg products). :contentReference[oaicite:19]{index=19}

Storage Conditions

Store at controlled room temperature; keep syringe in original packaging until use, protect from light and extreme temperatures. :contentReference[oaicite:20]{index=20}